Close Menu

NEW YORK (GenomeWeb News) – Investment bank Leerink Swann today upgraded Life Technologies to Outperform, noting the potential growth of the company's next-generation sequencing business.

In addition to the upgrade from Market Perform, analyst Dan Leonard increased the valuation of Life Tech's stock to a range of $59 to $63 from an earlier range of $43 to $45. He left full-year 2011 and 2012 revenues estimates unchanged at $3.74 billion and $3.77 billion, respectively. The earnings per share estimate also was unchanged at $3.71 for 2011 and $3.97 for 2012.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports on the struggle to meet the demand for rapid COVID-19 testing.

The Newsroom reports New Zealand is using genomics to trace the origins of its new coronavirus outbreak.

In Nature this week: researchers in Canada sequence the genome of the black mustard plant Brassica nigra, and more.

According to Bloomberg, Moderna has a $1.5 billion vaccine deal with the US to provide 100 million doses.